varenicline + placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Spinocerebellar Ataxia Type 3

Conditions

Spinocerebellar Ataxia Type 3

Trial Timeline

Oct 1, 2009 → Apr 1, 2011

NCT ID

NCT00992771

About varenicline + placebo

varenicline + placebo is a phase 2 stage product being developed by Pfizer for Spinocerebellar Ataxia Type 3. The current trial status is completed. This product is registered under clinical trial identifier NCT00992771. Target conditions include Spinocerebellar Ataxia Type 3.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02856581	Phase 3	Terminated	Sep 29, 2017	Apr 15, 2022	Lung Carcinoma
NCT01934023	Phase 2	Completed	Sep 1, 2013	Aug 1, 2015	Schizophrenia
NCT01850953	Approved	Completed	Jun 1, 2013	May 1, 2015	Craving
NCT01639560	Approved	Completed	Jan 1, 2013	Jun 1, 2016	Smoking
NCT01244061	Approved	Completed	Dec 1, 2010	Nov 1, 2012	Smoking Cessation
NCT01078298	Approved	Completed	Mar 1, 2010	Jun 1, 2012	Smoking Cessation
NCT01071187	Phase 2	UNKNOWN	Mar 1, 2010	Sep 1, 2011	Alcohol Dependence
NCT01010204	Approved	Completed	Jan 1, 2010	Mar 1, 2013	Smoking Cessation
NCT00992771	Phase 2	Completed	Oct 1, 2009	Apr 1, 2011	Spinocerebellar Ataxia Type 3
NCT00918307	Phase 3	Completed	Oct 1, 2009	Jul 1, 2014	HIV Infections
NCT00977249	Phase 2/3	UNKNOWN	Sep 1, 2009	Dec 1, 2011	Tobacco Dependence
NCT00744978	Phase 2	Completed	Jul 1, 2009	Nov 1, 2010	Alzheimer's Disease
NCT00803868	Phase 2/3	Terminated	May 1, 2009	May 1, 2010	Friedreich's Ataxia
NCT00835900	Phase 2	Completed	Mar 1, 2009	Jul 1, 2015	Smoking Cessation
NCT00944554	Approved	Completed	Oct 1, 2008	May 1, 2011	Recurrence
NCT00749944	Approved	Completed	Sep 1, 2008	Aug 1, 2009	Smoking Cessation
NCT00747643	Pre-clinical	Completed	Sep 1, 2008	Aug 1, 2010	Tobacco Dependence
NCT00937508	Approved	UNKNOWN	Jun 1, 2008	Jun 1, 2011	Smoking
NCT00595868	Phase 2	Completed	Mar 1, 2008	Jan 1, 2010	Tobacco Use Disorder
NCT00602927	Pre-clinical	Completed	Nov 1, 2007	Aug 1, 2008	Nicotine Dependence

Competing Products

15 competing products in Spinocerebellar Ataxia Type 3

See all competitors

Product	Company	Stage	Hype Score
KPS-0373, High dose + KPS-0373, Low dose	Kissei Pharmaceutical	Phase 3	76
KPS-0373, High dose + KPS-0373, Low dose + Placebo	Kissei Pharmaceutical	Phase 3	76
KPS-0373, High dose + KPS-0373, Low dose	Kissei Pharmaceutical	Phase 3	76
KPS-0373 + Placebo	Kissei Pharmaceutical	Phase 3	76
KPS-0373 + Placebo	Kissei Pharmaceutical	Phase 2	51
KPS-0373 + Placebo	Kissei Pharmaceutical	Phase 3	76
KPS-0373	Kissei Pharmaceutical	Phase 2	51
KPS-0373, High dose + KPS-0373, Low dose	Kissei Pharmaceutical	Phase 3	76
BIIB132 + BIIB132-Matching Placebo	Biogen	Phase 1	30
IVIG	Baxter	Phase 2	49
Intravenous Immune Globulin (IVIG)	Baxter	Phase 1	30
ARO-ATXN2 Injection + Placebo	Arrowhead Pharmaceuticals	Phase 1	30
Troriluzole + Placebo + Troriluzole	Biohaven	Phase 2/3	60
BHV-4157	Biohaven	Pre-clinical	18
troriluzole + Placebo	Biohaven	Phase 3	72

Other Products from Pfizer